Open AccessCardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
Author(s) -
Totzeck Matthias,
Mincu Raluca Ileana,
Rassaf Tienush
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006278
Subject(s) - medicine , bevacizumab , adverse effect , meta analysis , cancer , intensive care medicine , oncology , chemotherapy
The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life-threatening cardiovascular adverse effects could limit its use and may warrant specific follow-up strategies.